Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Puma Biotechnology, Inc.NASDAQ: PBYI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$196K, compared with $8.24M a year earlier. Trailing-twelve-month EBITDA was $44.91M. Over 3 fiscal years it compounded at +34.6% a year.
Context
- EBITDA amounted to 23.4% of revenue in FY2025, up 2.5 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $45.47M (-14.8%) for the fiscal year ending Dec 2026, a slowdown from the +11.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$196K-100.9% QoQ
- Last fiscal yearDec 2025
- $53.34M+11.0% YoY
- LTMMar 2026
- $44.91M-17.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -102.4% | -49.2% | +53.2 pp |
| 1 year | +11.0% | -14.8% | -25.7 pp |
| 3-year CAGR | +34.6% | -19.1% | -53.7 pp |
| 5-year CAGR | -21.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 53.34M USD
- Year-over-year change
- +11.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.34M | +11.0% |
| FY2024 | 2024-12-31 | 48.08M | +1.2% |
| FY2023 | 2023-12-31 | 47.52M | +117.1% |
| FY2022 | 2022-12-31 | 21.89M | +566.7% |
| FY2021 | 2021-12-31 | (4.69M) | — |
EBITDA vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.8% is the 7th highest of 11, against a peer median of -10.5%.
- EBITDA amounts to 19.8% of revenue for PBYI, versus a peer median of 230.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.91M USD | -17.8% | +34.6% | 19.8% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | -CN¥33.25M CNY | +92.9% | — | — |
| LTM Mar 2026 | -CA$36.08M CAD | -19.5% | — | — | |
| LTM Mar 2026 | -$38.09M USD | -800.9% | — | — | |
| LTM Mar 2026 | -$43.73M USD | +9.5% | — | 8329.5% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Jun 2026 | -$127.04M USD | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$134.03M USD | -1.8% | — | — | |
| LTM Mar 2026 | -$145.24M USD | -14.0% | — | — | |
| LTM Mar 2026 | -$191.95M USD | -32.3% | — | 387.1% | |
| LTM Sep 2026 | -$206.26M USD | -110.5% | — | — | |
| Peer median (excluding PBYI) | — | -10.5% | — | 230.9% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M |
| Cost of Revenue | 63.7M | 55.09M | 62.68M | 64.4M | 58.16M |
| Gross Profit | 189.45M | 172.94M | 172.96M | 166.06M | 170.21M |
| Gross Margin | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Research & Development | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M |
| Selling, General & Admin | 116.29M | 89.98M | 89.31M | 80.16M | 71.21M |
| Operating Expenses | 188.16M | 149.22M | 140.32M | 135.1M | 132.92M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| EBITDA | (4.69M) | 21.89M | 47.52M | 48.08M | 53.34M |
| EBITDA Margin | -1.9% | 9.6% | 20.2% | 20.9% | 23.4% |
| Operating Income | 1.29M | 23.72M | 32.64M | 30.97M | 37.3M |
| Operating Margin | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Interest Income | 160K | 813K | 2.61M | 4.72M | 4.08M |
| Interest Expense | 12.81M | 11.59M | 13.33M | 12.45M | 6.62M |
| Other Income / Expenses | (30.09M) | (23.26M) | (9.97M) | (6.87M) | (1.52M) |
| Income Before Tax | (28.8M) | 457K | 22.67M | 24.1M | 35.78M |
| Pre-Tax Margin | -11.4% | 0.2% | 9.6% | 10.5% | 15.7% |
| Income Tax Expense | 324K | 455K | 1.08M | (6.18M) | 4.67M |
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Net Margin | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| EPS (Basic) | (0.72) | 0.02 | 0.46 | 0.62 | 0.62 |
| EPS (Diluted) | (0.72) | 0.02 | 0.45 | 0.62 | 0.61 |
| Weighted Avg Shares | 40.64M | 44.67M | 47.13M | 48.65M | 50.01M |
| Weighted Avg Shares (Diluted) | 40.64M | 44.93M | 47.55M | 49.1M | 50.65M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.